CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 15 enrolled
Drug / intervention
intravitreal ranibizumab +1 moredrug
Likely dose
intravitreal ranibizumab 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01922154
NCT01922154Phase 4Completed
CompareCT.gov

Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma

Siriraj Hospital·interventional·Posted Aug 14, 2013·Updated Jul 16, 2021

In Brief

A Phase 4 clinical trial evaluating intravitreal ranibizumab and Trabeculectomy with mitomycinC for Glaucoma, Neovascular. Completed, enrolled 15 participants across 1 site.

Detailed Summary

To evaluate the effects of intravitreal ranibizumab (IVR) as adjunctive treatment for trabeculectomy with mitomycin C (TMC) in neovascular glaucoma (NVG).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Neovascular
CountriesThailand
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 14, 2013
Enrollment StartFeb 1, 2009
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 12.9 years ago

Interventions

intravitreal ranibizumabdrug

The patients received IVR (0.5 mg in 0.05 ml) injection through the pars plana in the operating room. A fornix-based conjunctival flap technique trabeculectomy with intraoperative mitomycin C was performed within 2 weeks after IVR.

Trabeculectomy with mitomycinCprocedure

All participant underwent trabeculectomy with mitomycinC , which is the standard procedure for refractory glaucoma.